Elin Svensson

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Mazariegos Herrera, Andres; Karlsson, Mats O.; Svensson, Elin M.; Dorlo, Thomas P. C.

Part of Journal of Antimicrobial Chemotherapy, 2026

• DOI for Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
• Download full text (pdf) of Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

Metcalfe, John Z.; Weir, Isabelle R.; Scarsi, Kimberly K.; Mendoza-Ticona, Alberto et al.

Part of The Lancet - Infectious diseases, p. 46-54, 2026

• DOI for A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
• Download full text (pdf) of A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

Kengo, Allan; Resendiz‐Galvan, Juan Eduardo; Najjemba, Letisha; Mugerwa, Henry et al.

Part of British Journal of Clinical Pharmacology, p. 3471-3481, 2025

• DOI for Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV
• Download full text (pdf) of Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

Heinrich, Norbert; de Jager, Veronique; Dreisbach, Julia; Gross-Demel, Petra et al.

Part of The Lancet Microbe, 2025

• DOI for Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
• Download full text (pdf) of Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Janssen, Saskia; Vongjarudech, Thanakorn; Karlsson, Mats O.; Upton, Caryn M. et al.

Part of Clinical Pharmacokinetics, p. 1885-1896, 2025

• DOI for Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
• Download full text (pdf) of Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Mazariegos Herrera, Andres; Karlsson, Mats O.; Svensson, Elin M.; Dorlo, Thomas P. C.

Part of Journal of Antimicrobial Chemotherapy, 2026

• DOI for Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
• Download full text (pdf) of Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

Metcalfe, John Z.; Weir, Isabelle R.; Scarsi, Kimberly K.; Mendoza-Ticona, Alberto et al.

Part of The Lancet - Infectious diseases, p. 46-54, 2026

• DOI for A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
• Download full text (pdf) of A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

Kengo, Allan; Resendiz‐Galvan, Juan Eduardo; Najjemba, Letisha; Mugerwa, Henry et al.

Part of British Journal of Clinical Pharmacology, p. 3471-3481, 2025

• DOI for Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV
• Download full text (pdf) of Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

Heinrich, Norbert; de Jager, Veronique; Dreisbach, Julia; Gross-Demel, Petra et al.

Part of The Lancet Microbe, 2025

• DOI for Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
• Download full text (pdf) of Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Janssen, Saskia; Vongjarudech, Thanakorn; Karlsson, Mats O.; Upton, Caryn M. et al.

Part of Clinical Pharmacokinetics, p. 1885-1896, 2025

• DOI for Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
• Download full text (pdf) of Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers

Zou, Yuanxi; de Jager, Veronique; Hesseling, Anneke C.; Diacon, Andreas H. et al.

Part of British Journal of Clinical Pharmacology, p. 957-967, 2025

• DOI for Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers
• Download full text (pdf) of Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers

Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology

van der Feltz, Isabella; Wen, Haini; Aarnoutse, Rob E.; Magis-Escurra, Cecile et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2597-2608, 2025

• DOI for Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology
• Download full text (pdf) of Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology

Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis

Meya, David B.; Cresswell, Fiona V.; Dai, Biyue; Engen, Nicole et al.

Part of New England Journal of Medicine, p. 2434-2446, 2025

• DOI for Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis

A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection

Zou, Yuanxi; Nedelman, Jerry; Karlsson, Mats O.; Svensson, Elin M.

Part of Clinical Pharmacokinetics, p. 1357-1365, 2025

• DOI for A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection
• Download full text (pdf) of A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection

Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas

Waalewijn, Hylke; Almett, Mounier; Wasmann, Roeland E.; Cressey, Tim R. et al.

Part of The Lancet Child and Adolescent Health, p. 274-282, 2025

• DOI for Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

Minja, Lilian Tina; van der Feltz, Isabella; Manyama, Christina; Mpagama, Stellah et al.

Part of The Lancet - Infectious diseases, p. 1219-1229, 2025

• DOI for Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
• Download full text (pdf) of Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Heinrich, Norbert; Manyama, Christina; Koele, Simon E.; Mpagama, Stellah et al.

Part of The Lancet - Infectious diseases, p. 1208-1218, 2025

• DOI for Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
• Download full text (pdf) of Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Koele, Simon E.; Stoycheva, Krista; Mtweve, Cyprian; Manyama, Christina et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2305-2313, 2025

• DOI for Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
• Download full text (pdf) of Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

Wijk, Marie; Wasmann, Roeland E.; Jacobson, Karen R.; Svensson, Elin M. et al.

Part of CPT, p. 1042-1049, 2025

• DOI for A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling
• Download full text (pdf) of A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Karlsson, Mats O. et al.

Part of CPT, p. 1252-1261, 2025

• DOI for Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
• Download full text (pdf) of Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Lin, Yu‐Jou; van der Laan, Louvina E.; Karlsson, Mats O.; Garcia‐Prats, Anthony J. et al.

Part of Clinical Pharmacology and Therapeutics, p. 1292-1302, 2025

• DOI for Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis
• Download full text (pdf) of Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

Palmer, Megan; Zou, Yuanxi; Hesseling, Anneke C.; van der Laan, Louvina et al.

Part of British Journal of Clinical Pharmacology, p. 1853-1864, 2025

• DOI for Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis
• Download full text (pdf) of Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

In reply to the Letter to the Editor regarding 'Development and Validation of a Time-Varying Correction Factor for QT Interval Assessment in Drug-Resistant Tuberculosis Patients'

Vongjarudech, Thanakorn; Svensson, Elin

Part of International Journal of Antimicrobial Agents, 2025

• DOI for In reply to the Letter to the Editor regarding 'Development and Validation of a Time-Varying Correction Factor for QT Interval Assessment in Drug-Resistant Tuberculosis Patients'

Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043

Koele, Simon E.; Heinrich, Norbert; De Jager, Veronique R.; Dreisbach, Julia et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1315-1323, 2025

• DOI for Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043
• Download full text (pdf) of Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043

Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

Raaijmakers, J.; Salillas, S.; Aarnoutse, R.; Svensson, Elin M. et al.

Part of Antimicrobial Agents and Chemotherapy, 2025

• DOI for Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system
• Download full text (pdf) of Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery

Wen, Haini; Sadiq, Muhammad Waqas; Friberg, Lena E.; Svensson, Elin M.

Part of CPT, p. 796-806, 2025

• DOI for Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery
• Download full text (pdf) of Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery

The importance of getting the dose right in the treatment of tuberculosis

Dudnyk, Andrii; Lutchmun, Wandini; Duarte, Raquel; Lange, Christoph et al.

Part of Breathe, 2025

• DOI for The importance of getting the dose right in the treatment of tuberculosis
• Download full text (pdf) of The importance of getting the dose right in the treatment of tuberculosis

Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Dooley, Kelly E. et al.

Part of International Journal of Antimicrobial Agents, 2025

• DOI for Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients
• Download full text (pdf) of Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system

Raaijmakers, Jelmer; Ruth, Mike M.; Schildkraut, Jodie A.; van den Hombergh, Erik et al.

Part of International Journal of Antimicrobial Agents, 2025

• DOI for Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system
• Download full text (pdf) of Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system

Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification

Dufault, Suzanne M.; Davies, Geraint R.; Svensson, Elin M.; Sloan, Derek J. et al.

Part of International Journal of Antimicrobial Agents, 2025

• DOI for Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification
• Download full text (pdf) of Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification

A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Lin, Yu-Jou; Zou, Yuanxi; Karlsson, Mats O.; Svensson, Elin

Part of Journal of Antimicrobial Chemotherapy, p. 2561-2569, 2024

• DOI for A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV

Montepiedra, Grace; Svensson, Elin; Wong, Weng Kee; Hooker, Andrew

Part of CPT, p. 270-280, 2024

• DOI for Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV
• Download full text (pdf) of Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV

A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease

Stemkens, Ralf; Lemson, Arthur; Koele, Simon E.; Svensson, Elin M. et al.

Part of Journal of Antimicrobial Chemotherapy, p. 3100-3108, 2024

• DOI for A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease
• Download full text (pdf) of A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Walter, Kerstin; te Brake, Lindsey H. M.; Lemm, Ann-Kathrin; Hoelscher, Michael et al.

Part of Journal of Antimicrobial Chemotherapy, p. 2607-2610, 2024

• DOI for Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures
• Download full text (pdf) of Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model

Salillas, Sandra; Raaijmakers, Jelmer; Aarnoutse, Rob E.; Svensson, Elin et al.

Part of Antimicrobial Agents and Chemotherapy, 2024

• DOI for Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model
• Download full text (pdf) of Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model

Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling

Koele, Simon E; Dorlo, Thomas P. C.; Upton, Caryn M; Aarnoutse, Rob E et al.

Part of CPT, p. 374-385, 2024

• DOI for Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling
• Download full text (pdf) of Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling

Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?

Nardotto, Glauco Henrique Balthazar; Svensson, Elin; Bollela, Valdes Roberto; Rocha, Adriana et al.

Part of Pharmaceutics, 2024

• DOI for Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?
• Download full text (pdf) of Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?

Conjugated hyperbilirubinemia associated with accidental rifapentine overdose

Yohane, M.; Naufal, F.; Endoza-Ticona, A. M.; Svensson, Elin M. et al.

Part of The International Journal of Tuberculosis and Lung Disease, p. 354-356, 2024

• DOI for Conjugated hyperbilirubinemia associated with accidental rifapentine overdose

Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Prins, H. A. B.; Zino, L.; Svensson, Elin M.; Verbon, A. et al.

Part of International Journal of Antimicrobial Agents, 2023

• DOI for Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)
• Download full text (pdf) of Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

Dierig, A.; Hoelscher, M.; Schultz, S.; Hoffmann, L. et al.

Part of Trials, 2023

• DOI for A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
• Download full text (pdf) of A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Susanto, Budi O.; Svensson, Elin M.; te Brake, Lindsey; Aarnoutse, Rob E. et al.

Part of International Journal of Antimicrobial Agents, 2023

• DOI for Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
• Download full text (pdf) of Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Litjens, Carlijn H. C.; Verscheijden, Laurens F. M.; Svensson, Elin M.; van den Broek, Petra H. H. et al.

Part of Antibiotics, 2023

• DOI for Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
• Download full text (pdf) of Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Ayoun Alsoud, Rami; Svensson, Robin J.; Svensson, Elin; Gillespie, Stephen H. H. et al.

Part of Frontiers in Pharmacology, 2023

• DOI for Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
• Download full text (pdf) of Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Stemkens, Ralf; de Jager, Veronique; Dawson, Rodney; Diacon, Andreas H. et al.

Part of Antimicrobial Agents and Chemotherapy, 2023

• DOI for Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
• Download full text (pdf) of Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Garcia-Prats, Anthony J.; Hoddinott, Graeme; Howell, Pauline; Hughes, Jennifer et al.

Part of The Lancet - Infectious diseases, p. 778-780, 2023

• DOI for Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Clinical standards for the management of adverse effects during treatment for TB

Singh, K. P.; Carvalho, A. C. C.; Centis, R.; D'Ambrosio, L. et al.

Part of The International Journal of Tuberculosis and Lung Disease, p. 506-519, 2023

• DOI for Clinical standards for the management of adverse effects during treatment for TB
• Download full text (pdf) of Clinical standards for the management of adverse effects during treatment for TB

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Zou, Yuanxi; Nedelman, Jerry; Lombardi, Antonio; Pappas, Frances et al.

Part of Clinical Pharmacokinetics, p. 1585-1593, 2022

• DOI for Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
• Download full text (pdf) of Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments

Bukkems, V. E.; van Hove, H.; Roelofsen, D.; Freriksen, J. J. M. et al.

Part of Clinical Pharmacokinetics, p. 1129-1141, 2022

• DOI for Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments
• Download full text (pdf) of Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments

Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment

van Beek, Stijn W.; Tanneau, Lénaïg; Meintjes, Graeme; Wasserman, Sean et al.

Part of OPEN FORUM INFECTIOUS DISEASES, 2022

• DOI for Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
• Download full text (pdf) of Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Denti, Paolo; Wasmann, Roeland E.; van Rie, Annelies; Winckler, Jana et al.

Part of Clinical Infectious Diseases, p. 141-151, 2022

• DOI for Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Keutzer, Lina; You, Huifang; Farnoud, Ali; Nyberg, Joakim et al.

Part of Pharmaceutics, 2022

• DOI for Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
• Download full text (pdf) of Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

Tanneau, Lénaïg; Karlsson, Mats; Diacon, Andreas H; Shenje, Justin et al.

Part of Clinical Pharmacokinetics, p. 1177-1185, 2022

• DOI for Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
• Download full text (pdf) of Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

De Jager, Veronique; Gupte, Nikhil; Nunes, Silvia; Barnes, Grace L. et al.

Part of American Journal of Respiratory and Critical Care Medicine, p. 1228-1235, 2022

• DOI for Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

Pharmacometrics - tools to assure optimal medicine use in low- and middle-income countries: Editorial

Abulfathi, Ahmed A.; Chaba, Linda A.; Svensson, Elin; Pillai, Goonaseelan C. et al.

Part of Frontiers in Pharmacology, 2022

• DOI for Pharmacometrics - tools to assure optimal medicine use in low- and middle-income countries: Editorial
• Download full text (pdf) of Pharmacometrics - tools to assure optimal medicine use in low- and middle-income countries: Editorial

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Sasaki, Tomohiro; Svensson, Elin; Wang, Xiaofeng; Wang, Yanlin et al.

Part of Antimicrobial Agents and Chemotherapy, 2022

• DOI for Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
• Download full text (pdf) of Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment

Koele, Simon E.; van Beek, Stijn W.; Maartens, Gary; Brust, James C. M. et al.

Part of Antimicrobial Agents and Chemotherapy, 2022

• DOI for Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment

Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease

Danho, Rabi; Schildkraut, Jodie A.; Zweijpfenning, Sanne M. H.; Svensson, Elin et al.

Part of Chest, p. 370-372, 2022

• DOI for Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
• Download full text (pdf) of Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease

Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Ruth, Mike Marvin; Raaijmakers, Jelmer; van den Hombergh, Erik; Aarnoutse, Rob et al.

Part of Clinical Microbiology and Infection, p. 4480-4480000000, 2022

• DOI for Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
• Download full text (pdf) of Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Litjens, Carlijn H. C.; Verscheijden, Laurens F. M.; Bolwerk, Celine; Greupink, Rick et al.

Part of Journal of clinical pharmacology, p. 385-396, 2022

• DOI for Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
• Download full text (pdf) of Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L.; Cramer, Yoninah S. et al.

Part of Clinical Pharmacology and Therapeutics, p. 873-881, 2022

• DOI for Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
• Download full text (pdf) of Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Pharmacometrics in tuberculosis: progress and opportunities

Wilkins, Justin J.; Svensson, Elin; Ernest, Jacqueline P.; Savic, Radojka M. et al.

Part of International Journal of Antimicrobial Agents, 2022

• DOI for Pharmacometrics in tuberculosis: progress and opportunities
• Download full text (pdf) of Pharmacometrics in tuberculosis: progress and opportunities

Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

Waalewijn, Hylke; Stol, Kim; van der Knaap, Linda; Fraaij, Pieter L. A. et al.

Part of AIDS, p. 2077-2079, 2022

• DOI for Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

Drug concentration at the site of disease in children with pulmonary tuberculosis

Lopez-Varela, Elisa; Abulfathi, Ahmed A.; Strydom, Natasha; Goussard, Pierre et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1710-1719, 2022

• DOI for Drug concentration at the site of disease in children with pulmonary tuberculosis
• Download full text (pdf) of Drug concentration at the site of disease in children with pulmonary tuberculosis

Clinical standards for the dosing and management of TB drugs

Alffenaar, J. W. C.; Stocker, S. L.; Forsman, L. Davies; Garcia-Prats, A. et al.

Part of The International Journal of Tuberculosis and Lung Disease, p. 483-+, 2022

• DOI for Clinical standards for the dosing and management of TB drugs

Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

Haas, David W.; Abdelwahab, Mahmoud Tareq; van Beek, Stijn W.; Baker, Paxton et al.

Part of Journal of Infectious Diseases, p. 147-156, 2022

• DOI for Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

de Rouw, Nikki; Boosman, Rene J.; Huitema, Alwin D. R.; Hilbrands, Luuk B. et al.

Part of Clinical Pharmacokinetics, p. 649-654, 2021

• DOI for Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
• Download full text (pdf) of Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa

van Beek, Stijn W.; Svensson, Elin; Tiono, Alfred B.; Okebe, Joseph et al.

Part of Parasites & Vectors, 2021

• DOI for Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa
• Download full text (pdf) of Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis

Abulfathi, Ahmed A.; de Jager, Veronique; van Brakel, Elana; Reuter, Helmuth et al.

Part of Frontiers in Pharmacology, 2021

• DOI for The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
• Download full text (pdf) of The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Tanneau, Lénaïg; Svensson, Elin; Rossenu, Stefaan; Karlsson, Mats

Part of CPT, p. 1538-1549, 2021

• DOI for Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
• Download full text (pdf) of Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Pharmacometrics meets statistics-A synergy for modern drug development

Ryeznik, Yevgen; Sverdlov, Oleksandr; Svensson, Elin; Montepiedra, Grace et al.

Part of CPT, p. 1134-1149, 2021

• DOI for Pharmacometrics meets statistics-A synergy for modern drug development
• Download full text (pdf) of Pharmacometrics meets statistics-A synergy for modern drug development

A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV

Bukkems, Vera E.; Post, Teun M.; Colbers, Angela P.; Burger, David M. et al.

Part of CPT, p. 161-172, 2021

• DOI for A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV
• Download full text (pdf) of A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies

Wasmann, Roeland E.; Svensson, Elin; Schalkwijk, Stein J.; Brüggemann, Roger J. et al.

Part of European Journal of Clinical Pharmacology, p. 727-733, 2021

• DOI for Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
• Download full text (pdf) of Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies

Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children

Wasmann, Roeland E.; Svensson, Elin; Walker, A. Sarah; Clements, Michelle N. et al.

Part of British Journal of Clinical Pharmacology, p. 2847-2854, 2021

• DOI for Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children
• Download full text (pdf) of Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

Cresswell, Fiona; Meya, David B.; Kagimu, Enock; Grint, Daniel et al.

Part of Clinical Infectious Diseases, p. 876-884, 2021

• DOI for High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

Sonawane, Vidhisha V.; Ruth, Mike M.; Pennings, Lian J.; Svensson, Elin et al.

Part of Antimicrobial Agents and Chemotherapy, 2021

• DOI for An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model

Pieterman, E. D.; van den Berg, S.; van der Meijden, A.; Svensson, Elin et al.

Part of Antimicrobial Agents and Chemotherapy, 2021

• DOI for Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model

Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis

Abdelwahab, Mahmoud Tareq; Court, Richard; Everitt, Daniel; Diacon, Andreas H. et al.

Part of Antimicrobial Agents and Chemotherapy, 2021

• DOI for Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Ngwalero, Precious; Brust, James C. M.; van Beek, Stijn W.; Wasserman, Sean et al.

Part of Antimicrobial Agents and Chemotherapy, 2021

• DOI for Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
• Download full text (pdf) of Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin

te Brake, Lindsey H. M.; de Jager, Veronique; Narunsky, Kim; Vanker, Naadira et al.

Part of European Respiratory Journal, 2021

• DOI for Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin
• Download full text (pdf) of Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Garcia-Prats, Anthony J.; Svensson, Elin; Winckler, Jana; Draper, Heather R. et al.

Part of Journal of Antimicrobial Chemotherapy, p. 3237-3246, 2021

• DOI for Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

van Beek, Stijn W.; ter Heine, Rob; Alffenaar, Jan-Willem C.; Magis-Escurra, Cecile et al.

Part of Clinical Pharmacokinetics, p. 943-953, 2021

• DOI for A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
• Download full text (pdf) of A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

Rifampicin can be given as flat-dosing instead of weight-band dosing

Susanto, Budi Octasari; Svensson, Robin J.; Svensson, Elin M.; Aarnoutse, Rob et al.

Part of Clinical Infectious Diseases, p. 3055-3060, 2020

• DOI for Rifampicin can be given as flat-dosing instead of weight-band dosing
• Download full text (pdf) of Rifampicin can be given as flat-dosing instead of weight-band dosing

Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Tanneau, Lénaïg; Karlsson, Mats O.; Svensson, Elin

Part of British Journal of Clinical Pharmacology, p. 913-922, 2020

• DOI for Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis
• Download full text (pdf) of Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens

Abulfathi, Ahmed A.; Assawasuwannakit, Piyanan; Donald, Peter R.; Diacon, Andreas H. et al.

Part of European Journal of Clinical Pharmacology, p. 1557-1565, 2020

• DOI for Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens

Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials

Svensson, Elin M.; Dian, Sofiati; te Brake, Lindsey; Ganiem, Ahmad Rizal et al.

Part of Clinical Infectious Diseases, p. 1817-1823, 2020

• DOI for Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials
• Download full text (pdf) of Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials

Clofazimine pharmacokinetics in patients with TB: dosing implications

Abdelwahab, Mahmoud Tareq; Wasserman, Sean; Brust, James C. M.; Gandhi, Neel R. et al.

Part of Journal of Antimicrobial Chemotherapy, p. 3269-3277, 2020

• DOI for Clofazimine pharmacokinetics in patients with TB: dosing implications

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Ruth, Mike Marvin; Koeken, Valerie A. C. M.; Pennings, Lian J.; Svensson, Elin et al.

Part of Journal of Antimicrobial Chemotherapy, p. 609-617, 2020

• DOI for Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
• Download full text (pdf) of Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Protein binding of rifampicin is not saturated when using high-dose rifampicin

Litjens, Carlijn H. C.; Aarnoutse, Rob E.; Kolmer, Eleonora W. J. van Ewijk-Beneken; Svensson, Elin et al.

Part of Journal of Antimicrobial Chemotherapy, p. 986-990, 2019

• DOI for Protein binding of rifampicin is not saturated when using high-dose rifampicin

Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus

Ruth, Mike Marvin; van Rossum, Mara; Koeken, Valerie A. C. M.; Pennings, Lian J. et al.

Part of Antimicrobial Agents and Chemotherapy, 2019

• DOI for Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

van Beek, Stijn W.; ter Heine, Rob; Keizer, Ron J.; Magis-Escurra, Cecile et al.

Part of Clinical Pharmacokinetics, p. 815-826, 2019

• DOI for Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin
• Download full text (pdf) of Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria

Ruth, Mike Marvin; Sangen, Jasper J. N.; Remmers, Karlijn; Pennings, Lian J. et al.

Part of Journal of Antimicrobial Chemotherapy, p. 935-943, 2019

• DOI for A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

Svensson, Elin; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Part of Clinical Pharmacokinetics, p. 591-599, 2018

• DOI for Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
• Download full text (pdf) of Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Svensson, Elin M.; Svensson, Robin J.; te Brake, Lindsey H. M.; Boeree, Martin J. et al.

Part of Clinical Infectious Diseases, p. 34-41, 2018

• DOI for The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
• Download full text (pdf) of The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Svensson, Robin J.; Svensson, Elin; Aarnoutse, Rob E.; Diacon, Andreas H. et al.

Part of Journal of Infectious Diseases, p. 991-999, 2018

• DOI for Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children

Svensson, Elin; du Bois, Jeannine; Kitshoff, Rene; de Jager, Veronique R. et al.

Part of British Journal of Clinical Pharmacology, p. 2384-2392, 2018

• DOI for Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
• Download full text (pdf) of Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children

Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Svensson, Elin M.; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Part of Journal of Pharmacokinetics and Pharmacodynamics, 2017

• DOI for Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Brill, Margreke JE; Svensson, Elin M; Pandie, Mishal; Maartens, Gary et al.

Part of International Journal of Antimicrobial Agents, p. 212-217, 2017

• DOI for Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis
• Download full text (pdf) of Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Svensson, Elin M.; Karlsson, Mats O

Part of Journal of Antimicrobial Chemotherapy, p. 3398-3405, 2017

• DOI for Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB
• Download full text (pdf) of Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Svensson, Elin M.; Acharya, Chayan; Clauson, Björn; Dooley, Kelly E. et al.

Part of AAPS Journal, p. 171-179, 2016

• DOI for Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Hennig, Stefanie; Svensson, Elin M; Niebecker, Ronald; Fourie, P Bernard et al.

Part of Journal of Antimicrobial Chemotherapy, p. 1330-1340, 2016

• DOI for Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Svensson, Elin M; Dosne, Anne-Gaëlle; Karlsson, Mats O

Part of CPT, p. 682-691, 2016

• DOI for Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin
• Download full text (pdf) of Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Svensson, Elin M.; Murray, Stephen; Karlsson, Mats O.; Dooley, Kelly E.

Part of Journal of Antimicrobial Chemotherapy, p. 1106-1114, 2015

• DOI for Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Svensson, Elin M.; Dooley, Kelly E.; Karlsson, Mats O.

Part of Antimicrobial Agents and Chemotherapy, p. 6406-6412, 2014

• DOI for Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Use of a linearization approximation facilitating stochastic model building

Svensson, Elin M.; Karlsson, Mats O.

Part of Journal of Pharmacokinetics and Pharmacodynamics, p. 153-158, 2014

• DOI for Use of a linearization approximation facilitating stochastic model building
• Download full text (pdf) of Use of a linearization approximation facilitating stochastic model building

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Svensson, Elin M.; Aweeka, Francesca; Park, Jeong-Gun; Marzan, Florence et al.

Part of Antimicrobial Agents and Chemotherapy, p. 2780-2787, 2013

• DOI for Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Svensson, Elin; van der Walt, Jan-Stefan; Barnes, Karen I.; Cohen, Karen et al.

Part of British Journal of Clinical Pharmacology, p. 465-476, 2012

• DOI for Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Gafar, Fajri; Wasmann, Roeland E.; McIlleron, Helen M.; Aarnoutse, Rob E. et al.

Part of European Respiratory Journal, 2023

• DOI for Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
• Download full text (pdf) of Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects

Koele, Simon E.; Phillips, Patrick P. J.; Upton, Caryn M.; van Ingen, Jakko et al.

Part of International Journal of Antimicrobial Agents, 2023

• DOI for Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects
• Download full text (pdf) of Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians

Diaz, Jessica M. Aguilar; Abulfathi, Ahmed A.; te Brake, Lindsey H. M.; van Ingen, Jakko et al.

Part of Respiration, p. 83-100, 2023

• DOI for New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
• Download full text (pdf) of New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians

Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis

Radtke, Kendra K.; Svensson, Elin; van der Laan, Louvina E.; Hesseling, Anneke C. et al.

Part of Expert Review of Clinical Pharmacology, p. 161-174, 2022

• DOI for Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

Sturkenboom, Marieke G. G.; Martson, Anne-Grete; Svensson, Elin; Sloan, Derek J. et al.

Part of Clinical Pharmacokinetics, p. 685-710, 2021

• DOI for Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
• Download full text (pdf) of Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance

Abulfathi, Ahmed A.; Donald, Peter R.; Adams, Kim; Svensson, Elin et al.

Part of British Journal of Clinical Pharmacology, p. 2123-2132, 2020

• DOI for The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

Jacobs, Tom G.; Svensson, Elin; Musiime, Victor; Rojo, Pablo et al.

Part of Journal of Antimicrobial Chemotherapy, p. 3433-3457, 2020

• DOI for Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
• Download full text (pdf) of Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Abulfathi, Ahmed Aliyu; Decloedt, Eric H.; Svensson, Elin M.; Diacon, Andreas H. et al.

Part of Clinical Pharmacokinetics, p. 1103-1129, 2019

• DOI for Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Pharmacometric Models to Improve Treatment of Tuberculosis

Svensson, Elin M

2016

• Download full text (pdf) of Pharmacometric Models to Improve Treatment of Tuberculosis

Modeling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant tuberculosis

Svensson, Elin M; Rossenu, Stefaan; Karlsson, Mats O

Pharmacodynamic interaction of bedaquiline and delamanid co-administration on QTcF interval prolongation

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L; Cramer, Yoninah S et al.

A novel approach to evaluate the design of pediatric pharmacokinetic studies focused on accurate dose selection

Zou, Yuanxi; Nedelman, Jerry; Karlsson O, Mats; Svensson M, Elin